Gastric Bypass is a Cost-Saving Procedure: Results from a Comprehensive Markov Model
Obesity is a growing public health problem in industrialized countries and is directly and indirectly responsible for almost 10 % of all health expenditures. Bariatric surgery is the best available treatment, however, associated with important economical expenditures. So, cost-effectiveness analysis of the available surgical options is paramount.
We developed a Markov model for three different strategies: best medical management, gastric band, and gastric bypass. The Markov model was constructed to allow for the evaluation of the impact of several obesity-related comorbidities. The results were derived for a representative population of morbidly obese patients, and subgroup analyses were performed for patients without comorbidities, patients with diabetes mellitus, different age, and body mass index (BMI) groups. Cost-effectiveness analysis was performed accounting for lifetime costs and from a societal perspective.
Gastric bypass is a dominant strategy, rendering a significant decrease in lifetime costs and increase in quality-adjusted life years (QALYs). Comparing with the best medical management, in the global population of patients with a BMI of >35 kg/m2, gastric bypass renders 1.9 extra QALYs and saves on average 13,244€ per patient. Younger patients, patients with a BMI between 40 and 50 kg/m2, and patients without obesity-related diseases are the ones with a bigger benefit in terms of cost effectiveness.
Gastric bypass surgery increases quality-adjusted survival and saves resources to health systems. As such, it can be an important process to control the ever-increasing health expenditure.
KeywordsObesity surgery Cost-effectiveness Markov model Gastric bypass
- 16.Hunink MGM. Decision making in health and medicine. Cambridge, UK: Cambridge University Press; 2001.Google Scholar
- 19.Wadden TA, Sternberg JA, Letizia KA, et al. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes. 1989;2(13):39–46.Google Scholar
- 23.Arias E. United States life tables, 2006. National vital statistics reports: from the Centers for Disease Control and Prevention (2010).Google Scholar
- 27.United States Environmental Protection Agency. Cardiovascular disease prevalence and mortality. Available from: http://cfpub.epa.gov/eroe/index.cfm?fuseaction=detail.viewInd&lv=list.listByAlpha&r=235292&subtop=381. Accessed 9 Jun 2012.
- 30.American Academy of Sleep Medicine. Cost justification for diagnosis and treatment of obstructive sleep apnea. Position statement of the American Academy of Sleep Medicine. Sleep. 2000;23(8):1017–8.Google Scholar
- 32.Potetz L. Cancer and medicare: a chartbook. Washington, DC: American Cancer Society; 2009.Google Scholar
- 33.National Institutes of Health. US Renal Data System (USRDS) annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health. http://www.usrds.org/adr.htm. 2010.